Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 236

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors

Senzer, Neil, Nemunaitis, John, Nemunaitis, Derek, Bedell, Cynthia, Edelman, Gerald, Barve, Minal, Nunan, Robert, Pirollo, Kathleen F, Rait, Antonina, Chang, Esther H·2013·Molecular Therapy
DOI 10.1038/mt.2013.32
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2013.32

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 42

  1. Lane, 1995, On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage, Philos Trans R Soc Lond, B, Biol Sci, 347, 83, 10.1098/rstb.1995.0013 · DOI
  2. Levine, 1991, The p53 tumour suppressor gene, Nature, 351, 453, 10.1038/351453a0 · DOI · Paper page
  3. Hollstein, 1994, Database of p53 gene somatic mutations in human tumors and cell lines, Nucleic Acids Res, 22, 3551
  4. Gudkov, 2003, The role of p53 in determining sensitivity to radiotherapy, Nat Rev Cancer, 3, 117, 10.1038/nrc992 · DOI · Paper page
  5. Isobe, 1994, Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection, Jpn J Cancer Res, 85, 1240, 10.1111/j.1349-7006.1994.tb02936.x · DOI
  6. Iwaya, 1991, Nuclear p53 immunoreaction associated with poor prognosis of breast cancer, Jpn J Cancer Res, 82, 835, 10.1111/j.1349-7006.1991.tb02710.x · DOI · Paper page
  7. Quinlan, 1992, Accumulation of p53 protein correlates with a poor prognosis in human lung cancer, Cancer Res, 52, 4828
  8. Thorlacius, 1993, Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor, Cancer Res, 53, 1637
  9. Thor, 1992, Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers, J Natl Cancer Inst, 84, 845, 10.1093/jnci/84.11.845 · DOI · Paper page
  10. Allred, 1993, Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer, J Natl Cancer Inst, 85, 200, 10.1093/jnci/85.3.200 · DOI · Paper page
  11. Hamada, 1996, The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers, J Cancer Res Clin Oncol, 122, 360, 10.1007/BF01220804 · DOI
  12. Xu, 1999, Systemic p53 gene therapy in combination with radiation results in human tumor regression, Tumor Targeting, 4, 92
  13. Cicalese, 2009, The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells, Cell, 138, 1083, 10.1016/j.cell.2009.06.048 · DOI · Paper page
  14. Bonizzi, 2012, The emerging role of p53 in stem cells, Trends Mol Med, 18, 6, 10.1016/j.molmed.2011.08.002 · DOI
  15. Nemunaitis, 2008, Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome, Future Oncol, 4, 759, 10.2217/14796694.4.6.759 · DOI
  16. Nemunaitis, 2011, Head and neck cancer: response to p53-based therapeutics, Head Neck, 33, 131, 10.1002/hed.21364 · DOI
  17. Nemunaitis, 2009, Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck, Clin Cancer Res, 15, 7719, 10.1158/1078-0432.CCR-09-1044 · DOI
  18. Senzer, 2009, A review of contusugene ladenovec (Advexin) p53 therapy, Curr Opin Mol Ther, 11, 54
  19. Nemunaitis, 2000, Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer, J Clin Oncol, 18, 609, 10.1200/JCO.2000.18.3.609 · DOI · Paper page
  20. Senzer, 2007, p53 therapy in a patient with Li-Fraumeni syndrome, Mol Cancer Ther, 6, 1478, 10.1158/1535-7163.MCT-07-0125 · DOI
  21. Swisher, 2003, Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy, Clin Cancer Res, 9, 93
  22. Daniels, 2012, The transferrin receptor and the targeted delivery of therapeutic agents against cancer, Biochim Biophys Acta, 1820, 291, 10.1016/j.bbagen.2011.07.016 · DOI · Paper page
  23. Daniels, 2006, The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells, Clin Immunol, 121, 159, 10.1016/j.clim.2006.06.006 · DOI · Paper page
  24. Daniels, 2006, The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer, Clin Immunol, 121, 144, 10.1016/j.clim.2006.06.010 · DOI · Paper page
  25. Xu, 2002, Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes, Mol Cancer Ther, 1, 337
  26. Xu, 1999, Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts, Hum Gene Ther, 10, 2941, 10.1089/10430349950016357 · DOI · Paper page
  27. Xu, 2002, Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery, Hum Gene Ther, 13, 469, 10.1089/10430340252792594 · DOI
  28. Xu, 2001, Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv, Mol Med, 7, 723, 10.1007/BF03401962 · DOI
  29. Yu, 2004, Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide, Nucleic Acids Res, 32, e48, 10.1093/nar/gnh049 · DOI
  30. Xu, 2001, Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy, J Control Release, 74, 115, 10.1016/S0168-3659(01)00324-8 · DOI
  31. Yu, 2004, A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene, Gene Ther, 11, 1434, 10.1038/sj.gt.3302304 · DOI
  32. Chrastina, 2011, Overcoming in vivo barriers to targeted nanodelivery, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 3, 421, 10.1002/wnan.143 · DOI · Paper page
  33. Davis, 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 464, 1067, 10.1038/nature08956 · DOI · Paper page
  34. Pirollo, 2006, Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery, Hum Gene Ther, 17, 117, 10.1089/hum.2006.17.117 · DOI
  35. Pirollo, 2007, Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system, Cancer Res, 67, 2938, 10.1158/0008-5472.CAN-06-4535 · DOI · Paper page
  36. Hallaj-Nezhadi, 2010, Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy, Pharmazie, 65, 855
  37. Guo, 2011, Recent advances in nonviral vectors for gene delivery, Acc Chem Res, 45, 971, 10.1021/ar200151m · DOI · Paper page
  38. Ahi, 2011, Adenoviral vector immunity: its implications and circumvention strategies, Curr Gene Ther, 11, 307, 10.2174/156652311796150372 · DOI · Paper page
  39. Monti, 2002, Tumour p53 mutations exhibit promoter selective dominance over wild type p53, Oncogene, 21, 1641, 10.1038/sj.onc.1205250 · DOI
  40. Harris, 1996, Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein, Cancer Gene Ther, 3, 121
  41. Wang, 2011, Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation, J Clin Invest, 121, 893, 10.1172/JCI44504 · DOI
  42. Fujiwara, 1994, Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene, Cancer Res, 54, 2287

Cited by

See all 236

Metadata

Authors
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2013-05
Volume
21
Issue
5
Pages
1096-1103
ISSN
1525-0016
DOI
10.1038/mt.2013.32
Cited by
236
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors. https://app.cochat.ai/papers/10.1038/mt.2013.32
The paper
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H. (2013). Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors. Molecular Therapy. https://doi.org/10.1038/mt.2013.32

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.